Nebivolol Macleods Pharma Uk

Nebivolol, the active ingredient in Nebivolol Macleods Pharma Uk, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and heart failure by lowering blood pressure and improving cardiac efficiency in adult patients.

GNH USA supplies Nebivolol Macleods Pharma Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for conditions within the cardiovascular disease spectrum where blood pressure control or cardiac function improvement is required.

Hypertension: reduces systolic and diastolic blood pressure to target levels. Heart failure: improves left ventricular ejection fraction and reduces symptoms of chronic heart failure.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: unusual tiredness or lack of energy. - Nausea: feeling of stomach upset. - Insomnia: difficulty falling or staying asleep. - Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction in the heart. - Symptomatic hypotension: sudden drop in blood pressure causing faintness. - Bronchospasm: narrowing of airways, especially in asthmatic patients. - Allergic reactions: rash, itching, or swelling of the face and throat. - Hepatic injury: abnormal liver function tests or jaundice.

Before initiating Nebivolol therapy, clinicians should evaluate patient-specific factors and monitor for potential risks.

Monitor blood pressure: ensure target levels are achieved without excessive drop. Assess cardiac function: review baseline heart rate and ECG for conduction abnormalities. Use caution in asthma: β‑blockade may precipitate bronchospasm. Review concomitant beta‑blockers: avoid additive effects on heart rate. Adjust dose in renal impairment: consider reduced clearance in severe kidney disease. Store at below 25°C: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Calcium channel blockers (verapamil, diltiazem): increased risk of bradycardia and AV block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma concentrations. - Clonidine withdrawal: abrupt cessation can cause rebound hypertension. - Non‑selective beta‑blockers: heightened risk of bronchospasm.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: combined antihypertensive action may require dose adjustment. - NSAIDs: can blunt antihypertensive response. - Digoxin: monitor for bradycardia. - Other antihypertensives: assess for excessive blood pressure lowering.